Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market cagr 7.5%

Pharmacogenomi cs

Technology & Theranostics & Companion Diagnostics (CDx)

Market

Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Scope: Industry Analysis, Market Size, Growth, Trends Till

Request Sample Report

Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Growth

Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market research reports indicate a growing market driven by advancements in personalized medicine. The global market size is estimated to reach $12.5 billion by 2025, with a CAGR of 8.6%. Increased adoption of precision medicine and targeted therapies in healthcare is driving market growth.

Companies Covered (Covid 19 Impact Covered)

◍ Qiagen NV

◍ GE Healthcare

◍ Agilent Technologies

◍ F Hoffman La Roche

◍ Foundation Medicine

◍ Thermo Fisher Scientific Inc.

◍ Leica Biosystems Nussloch GmBH

◍ Pfizer

The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market is highly competitive with companies such as Qiagen NV, GE Healthcare, Agilent Technologies, F Hoffman La Roche, Foundation Medicine, Thermo Fisher Scientific Inc., Leica Biosystems Nussloch GmBH, and Pfizer leading the market. These companies utilize advanced technologies to develop personalized medicine solutions, driving the growth of the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market.

- Qiagen NV: $1.58 billion (2019)

- GE Healthcare: Not available

- Agilent Technologies: $5.37 billion (2020)

- F Hoffman La Roche: CHF 58.32 billion (2020)

Market Segmentation

By Application

◍ Oncology

◍ Neurological Disorders

◍ Cardiovascular Disease

◍ Immunological Disorders

◍ Others

By Product

◍ PCR

◍ In-situ Hybridization

◍ Immunohistochemistry

◍ Sequencing

◍ Others

Request Sample Report